Log in | Register

Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies

Andre C. Kalil| Junfeng Sun
Systematic Review
Volume 37, Issue 3 / March , 2011

Pages 420 - 429

Abstract

Purpose

Low-dose steroids have shown contradictory results in trials and three recent meta-analyses. We aimed to assess the efficacy and safety of low-dose steroids for severe sepsis and septic shock by Bayesian methodology.

Methods

Randomized trials from three published meta-analyses were reviewed and entered in both classic and Bayesian databases to estimate relative risk reduction (RRR) for 28-day mortality, and relative risk increase (RRI) for shock reversal and side effects.

Results

In septic shock trials only (Marik meta-analysis; N = 965), the probability that low-dose steroids decrease mortality by more than 15% (i.e., RRR > 15%) was 0.41 (0.24 for RRR > 20% and 0.14 for RRR > 25%). For severe sepsis and septic shock trials combined, the results were as follows: (1) for the Annane meta-analysis (N = 1,228), the probabilities were 0.57 (RRR > 15%), 0.32 (RRR > 20%), and 0.13 (RRR > 25%); (2) for the Minneci meta-analysis (N = 1,171), the probability was 0.57 to achieve mortality RRR > 15%, 0.32 (RRR > 20%), and 0.14 (RRR > 25%). The removal of the Sprung trial from each analysis did not change the overall results. The probability of achieving shock reversal ranged from 65 to 92%. The probability of developing steroid-induced side effects was as follows: for gastrointestinal bleeding (N = 924), there was a 0.73 probability of steroids causing an RRI > 1%, 0.70 for RRI > 2%, and 0.67 for RRI > 5%; for superinfections (N = 964), probabilities were 0.81 (RRI > 1%), 0.76 (RRI > 2%), and 0.70 (RRI > 5%); and for hyperglycemia (N = 540), 0.99 (RRI > 1%), 0.97 (RRI > 2%), and 0.94 (RRI > 5%).

Conclusions

Based on clinically meaningful thresholds (RRR > 15–25%) for mortality reduction in severe sepsis or septic shock, the Bayesian approach to all three meta-analyses consistently showed that low-dose steroids were not associated with survival benefits. The probabilities of developing steroid-induced side effects (superinfections, bleeding, and hyperglycemia) were high for all analyses.

Keywords

SteroidsSepsisShock

References

  1. Schumer W (1976) Steroids in the treatment of clinical septic shock. Ann Surg 184:333–341
    • View reference on publisher's website
    • View reference on PubMed
  2. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, Duncan RC, Tendler MD, Karpf M (1984) The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 311:1137–1143
    • View reference on publisher's website
    • View reference on PubMed
  3. The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659–665
    • View reference on publisher's website
  4. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23:1430–1439
    • View reference on publisher's website
    • View reference on PubMed
  5. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26:645–650
    • View reference on publisher's website
    • View reference on PubMed
  6. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27:723–732
    • View reference on publisher's website
    • View reference on PubMed
  7. Chawla K, Kupfer Y, Goldman I, Tessler S (1999) Hydrocortisone reverses refractory septic shock. Crit Care Med 27(1):A33
    • View reference on publisher's website
  8. Yildiz O, Doganay M, Aygen B, Guven M, Kelestimur F, Tutuu A (2002) Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 6:251–259
    • View reference on publisher's website
    • View reference on PubMed
  9. Oppert M, Schindler R, Husung C, Offermann K, Gräf KJ, Boenisch O, Barckow D, Frei U, Eckardt KU (2005) Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 33:2457–2464
    • View reference on publisher's website
    • View reference on PubMed
  10. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871
    • View reference on publisher's website
    • View reference on PubMed
  11. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J, CORTICUS Study Group (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124
    • View reference on publisher's website
    • View reference on PubMed
  12. Minneci PC, Deans KJ, Eichacker PQ, Natanson C (2009) The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 15:308–318
    • View reference on publisher's website
    • View reference on PubMed
  13. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, Keh D, Kupfer Y, Oppert M, Meduri GU (2009) Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 301:2362–2375
    • View reference on publisher's website
    • View reference on PubMed
  14. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, Keh D, Briegel J, Beishuizen A, Dimopoulou I, Tsagarakis S, Singer M, Chrousos GP, Zaloga G, Bokhari F, Vogeser M, American College of Critical Care Medicine (2008) Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 36:1937–1949
    • View reference on publisher's website
    • View reference on PubMed
  15. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
    • View reference on publisher's website
    • View reference on PubMed
  16. Annane D, Trabold F, Sharshar T, Jarrin I, Blanc AS, Raphael JC, Gajdos P (1999) Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med 160:458–465
    • View reference on PubMed
  17. Center for Drug Evaluation and Research (CDER) (2005) Reviewer guidance on conducting a clinical safety review of a new product application and preparing a report on the review. US FDA, Rockville, MD
  18. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748
    • View reference on PubMed
  19. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
    • View reference on publisher's website
    • View reference on PubMed
  20. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR (2000) Bayesian methods in health technology assessment: a review. Health Technol Assess 4:1–130
    • View reference on PubMed
  21. Kalil AC, Sun J (2008) Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A Bayesian analysis. PLoS One 3:e2291
    • View reference on publisher's website
    • View reference on PubMed
  22. Kalil AC, Sun J (2008) How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design. Intensive Care Med 34:1804–1811
  23. Spiegelhatler DJ, Abrams KR, Myles JP (eds) (2004) Bayesian approaches to clinical trials and health-care evaluation. Wiley,West Sussex, p 170
  24. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R (2007) Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 131:954–963
    • View reference on publisher's website
    • View reference on PubMed
  25. Mussack T, Briegel J, Schelling G, Biberthaler P, Jochum M (2005) Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock. Clin Chem Lab Med 43:259–268
    • View reference on publisher's website
    • View reference on PubMed
  26. Luboshitzky R, Qupti G (2008) Corticosteroids for septic shock. N Engl J Med 358:2069, author reply 2070–2071
    • View reference on PubMed
  27. Dellinger RP (2008) Steroid therapy of septic shock: the decision is in the eye of the beholder. Crit Care Med 36:1987–1989
    • View reference on publisher's website
    • View reference on PubMed
  28. Moraes RB, Czepielewski MA, Friedman G (2009) Is the cortrosyn test necessary in high basal corticoid patients with septic shock? Crit Care Med 37:385–386, author reply 386–387
    • View reference on publisher's website
    • View reference on PubMed
  29. Salluh JI, Soares M (2008) New recommendations for the use of corticosteroids in sepsis: not so fast! Crit Care Med 36:2489–2490, author reply 2490
    • View reference on publisher's website
    • View reference on PubMed
  30. Lamontagne F, Meade MO (2008) Low-dose hydrocortisone did not improve survival in patients with septic shock but reversed shock earlier. ACP J Club 148:6
    • View reference on PubMed
  31. Seam N (2008) Corticosteroids for septic shock. N Engl J Med 358:2068–2069, author reply 2070–2071
    • View reference on publisher's website
    • View reference on PubMed
  32. Daley MR (2008) Corticosteroids for septic shock. N Engl J Med 358:2068, author reply 2070–2071
    • View reference on publisher's website
    • View reference on PubMed
  33. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C (2002) Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166:1197–1205
    • View reference on publisher's website
    • View reference on PubMed
  34. Li Y, Cui X, Li X, Solomon SB, Danner RL, Banks SM, Fitz Y, Annane D, Natanson C, Eichacker PQ (2008) Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis. Intensive Care Med 34:568–577
  35. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM, Edusepsis Study Group (2009) Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 180:861–866
    • View reference on publisher's website
    • View reference on PubMed
  36. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 36:222–231
  37. Bagshaw SM, Egi M, George C, Bellomo R, for the ANZICS Database Management Committee (2009) Early blood glucose control and mortality in critically ill patients in Australia. Crit Care Med 37:463–470
    • View reference on publisher's website
    • View reference on PubMed
  38. Petros A, Bennett D, Vallance P (1991) Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338:1557–1558
    • View reference on publisher's website
    • View reference on PubMed
  39. Lorente JA, Landin L, De Pablo R, Renes E, Liste D (1993) l-arginine pathway in the sepsis syndrome. Crit Care Med 21:1287–1295
    • View reference on publisher's website
    • View reference on PubMed
  40. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28:34–39
    • View reference on publisher's website
    • View reference on PubMed
  41. Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J, Glaxo Wellcome International Septic Shock Study Group (2004) Administration of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144–002). Crit Care Med 32:1–12
    • View reference on publisher's website
    • View reference on PubMed
  42. López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R (2004) Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32:21–30
    • View reference on publisher's website
    • View reference on PubMed
  43. Moraes RB, Czepielewski MA (2009) Corticosteroid therapy for severe sepsis and septic shock. JAMA 302:1643–1644, author reply 1644–1645
    • View reference on publisher's website
    • View reference on PubMed
  44. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171:242–248
    • View reference on publisher's website
    • View reference on PubMed
  45. Tandan SM, Guleria R, Gupta N (2005) Low dose steroids and adrenocortical insufficiency in septic shock: a double-blind randomised controlled trial from India. Am J Respir Crit Care Med 171:A24
  46. Rinaldi S, Adembri C, Grechi S, De Gaudio AR (2006) Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria. Crit Care Med 34:2334–2339
    • View reference on publisher's website
    • View reference on PubMed
  47. Cicarelli DD, Bensenor FE, Vieira JE (2006) Effects of single dose of dexamethasone on patients with systemic inflammatory response. Sao Paulo Med J 124:90–95
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement